Amgen's new research and development facility in San Francisco. (courtesy photo) It took nearly a year, but the impact of Amgen’s historic purchase of Horizon Therapeutics was finally felt on Feb. 6 when the company disclosed its earnings for the fourth quarter and full year 2023. Amgen, one of the largest biotechnology companies in the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
